Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ilagan, R.
Right arrow Articles by Carey, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ilagan, R.
Right arrow Articles by Carey, M.
Mol Cancer Ther. 2005;4:1662-1669
© 2005 American Association for Cancer Research

Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model

Romyla Ilagan1, Liquin Joann Zhang1, Jill Pottratz1, Kim Le1, Sussan Salas1, Meera Iyer3, Lily Wu2,3, Sanjiv S. Gambhir3 and Michael Carey1

Departments of 1 Biological Chemistry, 2 Urology, and 3 Molecular and Medical Pharmacology, School of Medicine, University of California at Los Angeles, Los Angeles, California

Requests for reprints: Romyla Ilagan, Department of Biological Chemistry, School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, CHS 33-142, Los Angeles, CA 90095-1737. Phone: 310-794-9636; Fax: 310-206-5272. E-mail: milagan{at}ucla.edu

The current understanding of the response of androgen receptor to pharmacologic inhibitors in prostate cancer is derived primarily from serum prostate-specific antigen (PSA) levels. In this study, we test whether a novel androgen receptor–specific molecular imaging system is able to detect the action of the antiandrogen flutamide on androgen receptor function in xenograft models of prostate cancer. Adenoviruses bearing an optical imaging cassette containing an androgen receptor–responsive two-step transcriptional amplification system were injected into androgen-dependent and hormone-refractory tumors of animals undergoing systemic time-controlled release of the antiandrogen flutamide. Imaging of tumors with a cooled charge-coupled device camera revealed that the response of AdTSTA to flutamide is more sensitive and robust than serum PSA measurements. Flutamide inhibits the androgen signaling pathway in androgen-dependent but not refractory tumors. Analysis of androgen receptor and RNA polymerase II binding to the endogenous PSA gene by chromatin immunoprecipitation revealed that flutamide treatment and androgen withdrawal have different molecular mechanisms. The application of imaging technology to study animal models of cancer provides mechanistic insight into antiandrogen targeting of androgen receptor during disease progression.


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: S.S. Gambhir is currently at the Molecular Imaging Program at Stanford, Stanford University School of Medicine, James H. Clark Center, E13 318 Campus Drive, Stanford, CA 94305-5472.

Received 6/15/05; revised 8/ 8/05; accepted 8/30/05.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.